Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 8/20 | 0.55 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4525931 | 0.83 | ROCK2 (0.53) | ALDH1A1PRKACAROCK1HTTKMT2A | |
| SCHEMBL4525453 | 0.83 | ROCK2 (0.53) | ALDH1A1PRKACAROCK1HTTKMT2A | |
| SCHEMBL2685328 | 0.79 | GPR142 (0.60) | NOX1GPR142KDM4EALDH1A1HPGD | |
| SCHEMBL2685334 | 0.79 | GPR142 (0.60) | NOX1GPR142KDM4EALDH1A1HPGD | |
| SCHEMBL4530261 | 0.78 | WNT3A (0.44) | PRKACAROCK1 | |
| SCHEMBL4527153 | 0.78 | WNT3A (0.44) | PRKACAROCK1 | |
| SCHEMBL2685860 | 0.78 | GPR142 (0.62) | NOX1GPR142KDM4EALDH1A1HPGD | |
| SCHEMBL4525533 | 0.78 | WNT3A (0.52) | GPR142ROCK1 | |
| SCHEMBL4522545 | 0.78 | WNT3A (0.52) | GPR142ROCK1 | |
| SCHEMBL2685524 | 0.77 | GPR142 (0.50) | NOX1GPR142KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785468-B2 | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions | AMGEN INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | AMGEN INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | IAPP, INSR, AMY2A | NOX1 2943/4885GPR142 2779/4885KDM4E 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.